Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of Tedopi versus standard chemotherapy in HLA-A2 positive advanced non-small cell lung cancer
MOH_2017-08-30_000772Phase 3Completed
- Sponsor
- OSE Immunotherapeutics
- Start
- Jul 2017
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Tedopi arm with Standard of care chemotherapy arm (2 arms). Primary endpoint: Overall survival. Started Jul 2017; status: completed.
02
Drugs
Tedopi
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2017-08-30_000772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-30_000772.